- Home
- IONS vs ARCC Comparison
IONS vs ARCC Comparison
Compare IONS & ARCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IONS | ARCC |
|---|---|---|
| Founded | 1989 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 12.8B |
| IPO Year | 1996 | 2004 |
Fundamental Metrics
Financial Performance| Metric | IONS | ARCC |
|---|---|---|
| Price | $75.09 | $18.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 10 |
| Target Price | ★ $90.14 | $21.60 |
| AVG Volume (30 Days) | 1.9M | ★ 7.5M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 10.66% |
| EPS Growth | ★ 21.71 | N/A |
| EPS | N/A | ★ 1.86 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $5.77 |
| Revenue Next Year | $76.97 | $2.29 |
| P/E Ratio | ★ N/A | $9.69 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.57 | $17.40 |
| 52 Week High | $86.74 | $23.42 |
Technical Indicators
Market Signals| Indicator | IONS | ARCC |
|---|---|---|
| Relative Strength Index (RSI) | 51.20 | 45.82 |
| Support Level | $69.05 | $17.49 |
| Resistance Level | $75.60 | $20.28 |
| Average True Range (ATR) | 2.36 | 0.41 |
| MACD | 0.66 | 0.07 |
| Stochastic Oscillator | 77.26 | 57.73 |
Price Performance
Historical ComparisonAbout IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
About ARCC Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.